From all 10 studies that were pooled into the meta-analysis, although not significant, associations were found between CYP3A4*1B polymorphism and prostate cancer risk in the allele model (G vs. A: OR = 1.32, CI = 0.91–1.93), (Figure 2A), as well in the dominant model (GG + AG vs. AA, OR = 1.41, CI = 0.95–2.09), (Figure 2B), indicating that the G allele and GG/AG genotypes may increase the risk of prostate cancer. This evidence concerns the gene CYP3A4 and prostate cancer.